Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
McKinsey
Express Scripts
Healthtrust
Queensland Health
Merck
Moodys
Baxter
Daiichi Sankyo

Generated: December 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ABIRATERONE ACETATE

« Back to Dashboard

Clinical Trials for Abiraterone Acetate

Trial ID Title Status Sponsor Phase Summary
NCT00473512 A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy Completed Cougar Biotechnology, Inc. Phase 1/Phase 2 The purpose of this study is to determine the maximum tolerated dose and evaluate the safety, tolerability, and activity at the recommended dose (maximum tolerated dose [MTD]) of abiraterone acetate (also known as CB7630) in participants with hormone refractory prostate (gland that makes fluid that aids movement of sperm) cancer (HRPC).
NCT00473746 Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer Completed Janssen Research & Development, LLC Phase 1/Phase 2 The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and anti‑tumor activities of abiraterone acetate (also referred to as CB7630) in patients with hormone refractory prostate cancer (HRPC).
NCT00474383 An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy Completed Cougar Biotechnology, Inc. Phase 2 The purpose of this study is to assess the anti-tumor activities and safety of abiraterone acetate in participants with prostate cancer (a disease in which cells in the prostate gland [a gland in the male reproductive system found below the bladder and in front of the rectum] become abnormal and start to grow uncontrollably, forming tumors) who have failed taxane (docetaxel)-based chemotherapy.
NCT00485303 An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy Completed Cougar Biotechnology, Inc. Phase 2 The purpose of this study is to evaluate the efficacy and safety of abiraterone acetate in participants with advanced prostate cancer (a disease in which cells in the prostate gland become abnormal and start to grow uncontrollably, forming tumors).
NCT00544440 An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma Completed Janssen Research & Development, LLC Phase 2 The purpose of this study is to investigate the effect of abiraterone acetate on levels of androgens and steroid metabolites in bone marrow plasma of patients with metastatic castration-resistant prostate cancer (CRPC).
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Abiraterone Acetate

Condition Name

Condition Name for Abiraterone Acetate
Intervention Trials
Prostate Cancer 77
Prostate Neoplasms 14
Stage IV Prostate Cancer 13
Prostatic Neoplasms 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Abiraterone Acetate
Intervention Trials
Prostatic Neoplasms 148
Adenocarcinoma 16
Carcinoma 10
Breast Neoplasms 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Abiraterone Acetate

Trials by Country

Trials by Country for Abiraterone Acetate
Location Trials
United States 662
Canada 65
Spain 43
United Kingdom 40
Japan 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Abiraterone Acetate
Location Trials
California 47
New York 39
Texas 36
Massachusetts 30
Maryland 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Abiraterone Acetate

Clinical Trial Phase

Clinical Trial Phase for Abiraterone Acetate
Clinical Trial Phase Trials
Phase 4 7
Phase 3 17
Phase 2/Phase 3 1
[disabled in preview] 105
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Abiraterone Acetate
Clinical Trial Phase Trials
Active, not recruiting 50
Recruiting 45
Completed 40
[disabled in preview] 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Abiraterone Acetate

Sponsor Name

Sponsor Name for Abiraterone Acetate
Sponsor Trials
Janssen Research & Development, LLC 30
National Cancer Institute (NCI) 19
Cougar Biotechnology, Inc. 12
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Abiraterone Acetate
Sponsor Trials
Industry 139
Other 137
NIH 21
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Mallinckrodt
Cerilliant
Colorcon
US Army
Dow
Medtronic
Queensland Health
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.